Trial | NCT01707914  Report issue

Title

Clinical Investigation on the Effects of Bayberry Juice Treatment in Adult Subjects With Features of Fatty Liver Disease
Effects of Chinese Bayberry Juice on Liver Enzymes and Plasma Antioxidant Activity in Adult Subjects With Features of Fatty Liver Disease: a Randomised Placebo-controlled Trial

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    44
Chinese bayberry, one of six Myrica species native to China, is rich in anthocyanins, and cyanidin-3-O-glucoside (C3G) was identified as a major anthocyanin component. In previous animal studies from us and other investigators, anthocyanins have been shown to ameliorate dyslipidemia and hepatic steatosis in different rodent models. The aim of the present study was to examine the effects of Chinese bayberry juice (CBJ) on the serum lipid profile and on levels of biomarkers related to antioxidant status in young adults with features of fatty liver disease.
Study Started
Jun 30
2012
Primary Completion
Oct 31
2012
Study Completion
Nov 30
2012
Last Update
Dec 04
2012
Estimate

Dietary Supplement Chinese bayberry juice

Consume 500 mL CBJ/d (250 mL CBJ twice daily)

Dietary Supplement placebo

Chinese bayberry juice Experimental

Consume 500 mL CBJ/d (250 mL CBJ twice daily)

Placebo Placebo Comparator

Consume 500 mL placebo/d (250 mL placebo twice daily)

Criteria 

Inclusion Criteria:

Subject inclusion criteria were age 18-25 y,
BMI [body weight divided by height squared (in kg/m2)] > 23,
lack of excessive alcohol ingestion confirmed by careful questioning by the primary physician and dietitians (consumption of less than 70 g alcohol in female and 140 g in male per week), and
the presence of two of the three following diagnostic criteria of the fatty liver disease: increased hepatic echogenicity compared to the spleen or the kidneys, blurring of liver vasculature and deep attenuation of the ultrasonographic signal.

Exclusion Criteria:

overuse of alcohol,
viral hepatitis,
type 1 or 2 diabetes,
gastrointestinal or connective diseases,
chronic pancreatitis,
liver cirrhosis,
kidney stones, or renal failure;
use of acetyl-salicylic acid or other antiplatelet drugs, statins of fibrates, oral hypoglycemic drugs, nitrates, nonsteroidal antiinflammatory drugs, corticosteroids, or drugs interfering with coagulation;
supplementation with vitamins or antioxidants.
No Results Posted